ATI Stock Recent News
ATI LATEST HEADLINES
Allegheny Technologies (ATI) closed the most recent trading day at $50, moving -1.88% from the previous trading session.
DALLAS , March 11, 2025 /PRNewswire/ -- ATI Inc. (NYSE: ATI) is disappointed to learn that one of two ratification votes for a labor agreement was unsuccessful. ATI's Specialty Rolled Products employees in Western Pennsylvania and Lockport, New York, and the United Steelworkers (USW) failed to ratify a successor labor agreement.
DALLAS , March 5, 2025 /PRNewswire/ -- ATI Inc. (NYSE: ATI) Executive Vice President and Chief Financial Officer Don Newman will speak at the 2025 JP Morgan Industrials Conference on March 12, 2025 at 3:10 p.m. ET. The link to the fireside chat is available at the News & Events section of www.ATImaterials.com/investors.
Investors need to pay close attention to ATI stock based on the movements in the options market lately.
DOWNERS GROVE, Ill. , March 4, 2025 /PRNewswire/ -- ATI Physical Therapy, Inc. (OTCMKTS: ATIP) ("ATI" or the "Company"), a nationally recognized outpatient physical therapy provider in the United States, announced today that on March 3, 2025, it closed a $26 million 8% second lien PIK convertible note financing.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
DALLAS , Feb. 28, 2025 /PRNewswire/ -- ATI Inc. (NYSE: ATI) announced that a tentative agreement has been reached with the leadership of the United Steelworkers (USW) on a new six-year Master Contract. This tentative agreement will be presented to the USW general membership for respective ratification votes.
Received overwhelming shareholder support in favour of take-private transaction with Aditxt Advanced key pipeline programs, engaged regulatory authorities on ATI-1801 and preparing ATI-1701 for an Investigational New Drug submission Further strengthened government partnerships, reinforcing Appili's position as a key player in biodefense and infectious disease solutions. HALIFAX, Nova Scotia, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced its financial and operational results for the third quarter of its fiscal year 2025, which ended on December 31, 2024.
ATI's new additive manufacturing facility includes the industry's largest format and most advanced capabilities.
World-class facility includes industry's largest format, most advanced capabilities MARGATE, Fla. , Feb. 13, 2025 /PRNewswire/ -- ATI Inc. (NYSE: ATI) celebrated the commissioning of its world-class Additive Manufacturing Products facility, bringing on-line the most advanced large-format, metal additive manufacturing capabilities in the industry.